In this guide
Does compounding pharmacy work qualify for the R&D tax credit?
It can. Formulations, sterile processes, and analytical methods that rest on chemistry, microbiology, and pharmaceutics, face real technical uncertainty, and get worked out through documented iteration may qualify.
The line is between building something new and following a known formula. Filling a USP monograph or a published vendor formula as written does not count. Building a dosage form, a beyond-use date, or a method that did not exist before often does.
How does the four-part test apply to compounding?
Every activity has to pass all four parts of the IRS test in Section 41(d), applied to the work at the bench and in the cleanroom.
- 01
Permitted purpose
The work aims to improve the stability, potency, sterility, or deliverability of a formulation, process, or analytical method.
- 02
Technological in nature
It rests on pharmaceutical chemistry, microbiology, pharmacokinetics, and analytical science.
- 03
Elimination of uncertainty
At the outset, the pharmacist does not know which base, excipient, or process setting will hold potency and stability.
- 04
Process of experimentation
Test batches, forced degradation, and structured reformulation, not following a monograph or a vendor formula as written.
What does qualifying compounding R&D look like?
Three illustrative examples, each written to show work that can meet all four parts of the test.
Extending the beyond-use date on a pediatric oral suspension without dyes
A 503A pharmacy needed a longer beyond-use date for a pediatric suspension made from tablets, with no commercial liquid available.
Suspending vehicles, pH, and preservative systems were tested against a stability-indicating HPLC method until potency held well past the USP default.
Terminally sterilized prefilled syringes for the operating room
A 503B outsourcing facility developed a ready-to-administer anesthesia syringe for hospital clients.
Concentration, container-closure, and autoclave cycle settings were revised across validation runs until sterility, endotoxin, and potency all passed together.
A transdermal gel for patients that will not take a pill
A veterinary compounding pharmacy reformulated an oral feline medication into an ear-applied transdermal gel.
Penetration enhancers and base ratios were iterated against absorption and dosing consistency, since no reference formulation existed for the species.
Which compounding and lab activities qualify?
Where work lands across 503A, 503B, veterinary, nuclear, and analytical settings, and the records that support it.
| Activity | Why it may qualify | Records | Status |
|---|---|---|---|
| Novel formulation development | New dosage forms, versions without problem excipients, and drug-shortage substitutes with no reference formula to follow. | Records: Formulation worksheets, trial batch records | Can qualify |
| Beyond-use date and stability studies | Extending beyond-use dates past USP 795 and 797 defaults through stability-indicating testing. | Records: Stability protocols, HPLC data | Can qualify |
| Sterile process validation | Sterilization cycles, depyrogenation, and aseptic processes designed and validated for new 503B products. | Records: Validation runs, media fills, endotoxin data | Can qualify |
| Analytical method development | Potency and stability-indicating methods built for new matrices like creams, pellets, and suspensions. | Records: Method validation reports | Can qualify |
| Veterinary dosage forms | Species-specific dosage forms and palatability work aimed at reliable dosing, transdermals, and large-animal forms where no reference formulation exists. Flavor for its own sake does not count. | Records: Dosing trials, formulation logs | Can qualify |
| Radiopharmaceutical preparation | Labeling efficiency and kit quality control methods developed for new isotopes and theranostic agents. | Records: Labeling yield logs, QC records | Can qualify |
| Contract formulation work | Can count when the pharmacy or lab's payment depends on the work succeeding and it keeps substantial rights to use the results. Work the client pays for regardless of outcome is treated as funded. | Records: Contracts, payment terms, rights to results | Depends on facts |
| Routine compounding and release testing | Filling a known formula or running a validated test carries no technical uncertainty. | Records: Not applicable | Excluded |
What compounding costs count toward the credit?
Three kinds of spending carry almost every compounding claim. Wages are usually the largest.
Wages
Time pharmacists, compounding technicians, and QA and QC staff spent on development and validation work, and the people who directly supervised or directly supported it.
Supplies
APIs, excipients, failed batches, media fills, and stability samples used up in development work.
Contract research
65% of what you paid outside firms for qualified research done on your behalf, under an agreement made before the work, when you pay whether or not the work succeeds and have a right to the results.
A credit can offset tax dollar for dollar. A $100,000 credit can offset up to $100,000 of income tax, while a $100,000 deduction at a 37% rate is worth $37,000. Claiming the credit also reduces your research deduction by the same amount, or the credit can be taken at a reduced amount instead, so the net gain is less than the full credit.
How does an R&D study work for a compounding pharmacy?
Four steps, built around how your pharmacists and lab staff already work.
- 01
Discovery call
Thirty minutes to size the likely credit and the strongest expense categories for your pharmacy or lab.
- 02
Technical interview
Pharmacists, technicians, and QA staff describe the work in their own terms. We find the experimentation inside it.
- 03
Credit calculation
Both federal methods are run, and development work is separated from routine compounding.
- 04
Filing support
A package your CPA can file from, with the records needed to support the claim if the IRS asks questions.
Common questions from compounding pharmacies
Do failed compounding batches count toward the R&D credit?
They can. The formulations that did not work can be what the IRS means by a process of experimentation, and the materials used up in them can be qualified supplies. They are often the strongest part of the file when the records still exist.
Does a 503B outsourcing facility qualify differently than a 503A pharmacy?
The same four-part test applies to both. 503B facilities often have more sterile process and validation work, while 503A pharmacies often have more formulation and beyond-use date work. Both can qualify.
Do cleanroom buildouts and USP 800 upgrades count?
No. Facility construction and compliance upgrades are not research under the credit. The formulation, validation, and method work done inside the facility is where qualifying activity usually sits.
Can a pharmacy claim the credit for years it already filed?
Often, yes. Years that are still open, usually the last three, can be claimed on an amended return, and the credit can produce a refund only to the extent it reduces tax already paid. Partnerships under the federal partnership audit rules file an administrative adjustment request instead, and the partners generally see the benefit on a later year's return rather than as a refund for the earlier year. The payroll tax option for small businesses has to be chosen by the return's due date, including extensions, so it is usually not available for past years.